Treatment of whole blood (WB) and red blood cells (RBC) with S-303 inactivates pathogens and retains in vitro quality of stored RBC.
A pathogen inactivation (PI) process has been developed using the frangible anchor linker effector (FRALE) compound S-303. A series of experiments were performed in whole blood (WB) to measure the level of viral and bacterial inactivation. The results showed that 0.2mM S-303 and 2mM glutathione (GSH) inactivated >6.5 logs of HIV, >5.7 logs of Bluetongue virus, >7.0 logs of Yersinia enterocolitica, 4.2 logs of Serratia marcescens, and 7.5 logs of Staphylococcus epidermidis. Recent development for S-303 is focused on optimization of the PI process for red blood cell concentrates (RBC). A series of studies in RBC showed that 0.2mM S-303 and 20mM GSH inactivated approximately 5 logs or greater of Y. enterocolitica, E. coli, S. marcescens, S. aureus, HIV, bovine viral diarrhoea virus, bluetongue virus and human adenovirus 5. In both applications of the S-303 process, in vitro parameters of RBC function and physiology were retained compared to conventional RBC. Results from these studies indicate that S-303 can be applicable for PI of RBC and WB.
Mufti
N A
NA
Cerus Corporation, 2411 Stanwell Drive, Concord, CA 94583, USA. nmufti@cerus.com
Erickson
A C
AC
North
A K
AK
Hanson
D
D
Sawyer
L
L
Corash
L M
LM
Lin
L
L
D000166:Acridines / Q000494:pharmacology*; D000477:Alkylating Agents / Q000494:pharmacology; D000818:Animals; D001769:Blood / Q000187:drug effects* / Q000382:microbiology / Q000821:virology; D001793:Blood Preservation / Q000379:methods*; D017848:Blood-Borne Pathogens / Q000302:isolation & purification; D002417:Cattle; D002478:Cells, Cultured; D015169:Colony Count, Microbial; D004202:Disinfectants / Q000494:pharmacology; D004203:Disinfection / Q000379:methods; D004912:Erythrocytes / Q000187:drug effects* / Q000382:microbiology / Q000821:virology; D004926:Escherichia coli / Q000187:drug effects / Q000502:physiology; D005240:Feasibility Studies; D006801:Humans; D016555:Matched-Pair Analysis; D009588:Nitrogen Mustard Compounds / Q000494:pharmacology*; D011786:Quality Control; D040141:Staphylococcaceae / Q000187:drug effects / Q000502:physiology; D015008:Yersinia enterocolitica / Q000187:drug effects / Q000502:physiology
C506266:(N,N-bis(2-chloroethyl))-2-aminoethyl-3-((acridin-9-yl)amino)propionate; D000166:Acridines; D000477:Alkylating Agents; D004202:Disinfectants; D009588:Nitrogen Mustard Compounds